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R. japonica is the speciﬁ  c patho-
gen of Japanese spotted fever, which 
has been found mainly in southwest-
ern Japan (5). The present strain, 
closely related to R. japonica, is likely 
to have been isolated from H. hystricis 
in Thailand because R. japonica fre-
quently has been isolated, or detected 
by PCR, from the same tick species 
in Japan (6). Such tick species–spec-
iﬁ  city of SFGR should be considered 
when speculating on any geopatholog-
ic relationships of rickettsioses among 
different SFGR-endemic areas. Previ-
ous reports on spotted fever–positive 
results of human serosurveys (7,8) 
and on a clinical case (9) in northern 
Thailand may provide epidemiologic 
background. In Asia, multiple species 
of rickettsiea (e.g., R. japonica, R. hei-
longjiangensis, R. honei) are the caus-
ative agents of spotted fever rickettsi-
oses, so the agent closely related to R. 
japonica could cause spotted fever in 
Thailand. Additionally, R. japonica 
has been found in Korea (10), and our 
current study indicates that R. japoni-
ca and its genetic variants are widely 
distributed in Far Eastern countries, 
including Japan (Grant-in-Aid for 
International Cooperative Research, 
unpub. data). Therefore, the epidemi-
ology and genetic variation of SFGR 
throughout Asia should be examined 
by molecular studies.
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Segniliparus 
rugosus Infection, 
Australia
To the Editor: Recently, a female 
teenager with cystic ﬁ  brosis who resid-
ed in tropical north Queensland, Aus-
tralia, was found to be infected with 
Segniliparus rugosus. She was ho-
mozygous for the deltaF508 mutation, 
had well-preserved lung function, and 
regularly played competitive sports. 
Unlike many cystic ﬁ  brosis patients, 
she did not have a history of chronic 
Pseudomonas aeruginosa infections, 
but  Stenotrophomonas maltophilia 
and Achromobacter xylosoxidans had 
been previously isolated from her spu-
tum. In May 2007, she described re-
duced exercise tolerance and increased 
cough with excess sputum production. 
Lung function testing showed modest 
spirometric decline. A computed to-
mographic scan of the chest showed 
signiﬁ  cant mucus plugging and bron-
chiectasis, uncommon without previ-
ous P. aeruginosa infection. Sputum 
was 3+ smear positive for acid-fast 
bacilli (AFB), and S. rugosus was iso-
lated from liquid culture. Empiric an-
timicrobial drug therapy was changed 
to rifabutin and co-trimoxazole be-
cause these drugs have been effective 
in previous cases (1). Clinically, the 
patient showed response to the treat-
ment. After 12 months of treatment, 
her sputum was still 3+ positive for 
AFB, and S. rugosus was again found 
in culture. She was referred to a pe-
diatric teaching hospital in Brisbane 
with worsening respiratory symptoms 
precipitated by inﬂ  uenza B infection. 
Antimicrobial drug therapy with in-
travenous imipenem, oral moxiﬂ  oxa-
cin, and co-trimoxazole for 2 weeks 
resulted in clinical improvement but 
little reduction in smear positivity.
The initial AFB smear-positive 
sputum specimen underwent routine 
decontamination with sodium hydrox-
ide and neutralization and was inocu-
lated into radiometric 12B vials (Bec-
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 4, April 2009  611 LETTERS
ton Dickinson, Sparks, MD, USA). 
The culture was positive after 6 days’ 
incubation and was referred to the 
state reference laboratory in Brisbane. 
The culture was smeared and stained 
with the Ziehl-Neelsen method, which 
showed short, pale AFB.
A crude boil DNA preparation was 
made from the positive culture, and an 
in-house multiplex PCR to identify 
Mycobacterium spp. was performed 
(2). No PCR products were detected, 
and the Mycobacterium genus-speciﬁ  c 
band was absent. Similarly, no Myco-
bacterium  genus band was detected 
by using a PCR-hybridization method 
(Common Mycobacteria line probe 
assay, Hain Lifesciences GmbH, Neh-
ren, Germany) (3). DNA sequencing 
was performed on the Segniliparus ru-
gosus strain NQ1 (GenBank accession 
no. FJ593188), and a 1,250-bp frag-
ment of the ribosomal 16S loci was 
obtained. A BLAST search (GenBank) 
was then performed on the sequence 
information obtained. The DNA se-
quence gave a 100% match to that of 
Segniliparus rugosus (GenBank ac-
cession no. AY608920) (4).
Drug susceptibility testing (DST) 
was attempted by using disk diffusion 
with Mueller-Hinton plates but was 
unsuccessful because of insufﬁ  cient 
growth and indistinct margins. A com-
mercially available microbroth dilu-
tion assay was used to determine the 
MICs for 12 antimicrobial drugs. The 
Sensititre Broth MIC Method for Rap-
idly Growing Mycobacteria, Nocar-
dia, and Other Aerobic Actinomycetes 
(Trek Diagnostic Systems, Cleveland, 
OH, USA) was used according to 
manufacturer’s instructions (5). How-
ever, problems still occurred because 
of inadequate growth of the organism 
using the testing media approved for 
mycobacteria (6,7). Superior results 
were obtained when the cation-ad-
justed Mueller-Hinton broth with TES 
buffer (Trek Diagnostic Systems), 
which is used routinely in this assay, 
was substituted with an internally pre-
pared Middlebrook 7H9 broth (Becton 
Dickinson) (1). DST results are similar 
to those previously reported for other 
strains of S. rugosus (Table) (1).
The strain had rough, wrinkled 
colonial morphology on both blood 
agar and 7H11 plates. Growth was 
optimal at 35°C on 7H11 media. 
Arylsulfatase activity was weakly 
positive at 3 days and positive at 14 
days. Growth on Lowenstein-Jensen 
(LJ) medium and on LJ with 5% so-
dium chloride medium occurred at 
6–7 days. The strain was negative 
for both nitrate reductase and tween 
hydrolysis. Mycolic acid high-pres-
sure liquid chromotography was per-
formed (8), and the pattern obtained 
matched that of type strain CDC 945 
(AY608920) previously reported (4). 
The pattern had a double cluster of 
adjoining eluting peaks with the last 
peak co-eluting with the internal high 
standard.
Only 3 other cases of Segnilipar-
us spp. infection (none from Australia) 
have been reported. More remains to 
be learned about the efects of lung 
infections with Segniliparus spp. in 
cystic ﬁ  brosis patients. Although this 
patient improved clinically after treat-
ment with antimicrobial drugs, she is 
still infected and will likely remain 
chronically infected. Because this ge-
nus is acid fast by the Ziehl-Neelsen 
method, laboratory workers and cli-
nicians must be aware that AFB seen 
in pulmonary specimens from cystic 
ﬁ   brosis patients are not necessarily 
from the genus Mycobacterium and 
may be from the genus Segniliparus. 
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Table. Antimicrobial susceptibility patterns for Segniliparus rugosus strain in a cystic 
fibrosis patient, Australia 
Antimicrobial agent  MIC, μg/mL 
Amikacin >128
Amoxicillin/clavulanic acid (ratio 2:1)  64/32
Cefoxitin 64
Ceftriaxone >64
Ciprofloxacin 4
Clarithromycin 16
Gatifloxacin 0.5
Imipenem 1
Linezolid 64
Minocycline >32
Tobramycin >64
Trimethoprim/sulfamethoxazole 2/38LETTERS
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Multigenotype 
Q Fever Outbreak, 
the Netherlands
To the Editor: Q fever is a 
zoonosis caused by Coxiella burnetii 
(1). An ongoing Q fever outbreak 
has occurred in the Netherlands since 
2007; incidence rates have increased 
>50-fold compared with the baseline 
rate (2). The source of this outbreak 
is unknown. Identifying the source of 
an infection is complicated because 
of difﬁ  culties in obtaining sufﬁ  cient 
clinical and/or environmental samples 
for testing. Molecular diagnosis of Q 
fever has focused on the use of serum 
samples. Up-to-date genotyping of C. 
burnetii has depended on cultivation 
and enrichment of the isolate before 
analysis (3). We report multiple-locus 
variable-number tandem repeat analy-
sis (MLVA) typing of C. burnetii for a 
variety of human and animal clinical 
samples obtained from different loca-
tions in the Netherlands (Table).
Severe pneumonia developed 
in patient 1 after close contact with 
sheep (ewes) and intimate cuddling 
with a newborn lamb. Patients 2 and 3 
(a dairy goat farmer and his wife from 
another village) tested positive for Q 
fever after a large part of their goat 
herd aborted offspring. The farmer 
had no clinical symptoms; his wife had 
mild symptoms that disappeared spon-
taneously within 2 days. No samples 
from any of the goats were available. 
Two additional patients were tested, 1 
of which lived in the same village as 
patients 2 and 3.
Swab specimens from all sheep 
and lambs tested in the ﬁ  rst  case 
yielded identical MLVA genotypes. 
The same genotype was also found 
in patient 1 but not in the other ex-
amined samples, implicating sheep 
as the origin of patient 1’s infection. 
Although patients 2 and 3 lived to-
gether, the genotype found in patient 
2 differed from the (partial) genotype 
found in patient 3. Yet another geno-
type was found in a patient from the 
same village (patient 4). However, an 
identical genotype found in patient 2 
was found in a patient from a distant 
village (patient 5). The village had 
only 1 goat farm, and if this herd of 
goats was the source of infection for 
the farmer, his wife, and patient 4, it 
would have contained >1 genotype. 
At least 1 of the obtained genotypes 
has spread over a wider surface area 
in the Netherlands.
Our results show that the unpre-
cedented, ongoing Q fever outbreak 
in the Netherlands involves multiple 
genotypes of C. burnetii. Because 
most of the genotypes differ only by 
a single repeat difference, they might 
represent microvariants of a hypervir-
ulent strain that has been introduced in 
the Dutch animal population. MLVA 
schemes with up to 17 markers have 
been previously reported (3). In this 
“proof of concept” (applying direct 
genotyping of C. burnetti on clinical 
samples), we focused on the 3 short-
est repeat units because we believed 
that these units might have the highest 
à priori chance of successful ampliﬁ  -
cation in clinical samples (especially 
in serum/plasma). Similar genotypes 
as those reported here were found 
in the MLVA database (http://mlva.
u-psud.fr), but these similarities need 
conﬁ  rmation by using more markers. 
Although using only 3 markers may 
lead to poor discriminatory power, 
we were still able to distinguish 4 dif-
ferent genotypes in a relatively small 
collection of serum samples. We are 
currently exploring the use of addi-
tional MLVA markers. 
Our results also show a poor cor-
relation between DNA load and clini-
cal symptoms. Multiple human and 
animal clinical samples, including 
serum and plasma, throat or genital 
swabs, or sputum and urine, may be 
useful for direct genotyping and out-
break source tracking. 
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Letters
Letters commenting on recent articles 
as well as letters reporting cases, out-
breaks, or original research are wel-
come. Letters commenting on articles 
should contain no more than 300 
words and 5 references; they are more 
likely to be published if submitted 
within 4 weeks of the original article’s 
publication. Letters reporting cases, 
outbreaks, or original research should 
contain no more than 800 words 
and 10 references. They may have 1 
Figure or Table and should not be di-
vided into sections. All letters should 
contain material not previously pub-
lished and include a word count.